Verification of predicted alternatively spliced Wnt genes reveals two new splice variants (CTNNB1 and LRP5) and altered Axin-1 expression during tumour progression by Pospisil, H. et al.
BioMed CentralBMC Genomics
ssOpen AcceResearch article
Verification of predicted alternatively spliced Wnt genes reveals 
two new splice variants (CTNNB1 and LRP5) and altered Axin-1 
expression during tumour progression
Heike Pospisil1, Alexander Herrmann2, Kristine Butherus3, Stefan Pirson4, 
Jens G Reich2 and Wolfgang Kemmner*5
Address: 1Center for Bioinformatics, University of Hamburg, Bundesstrasse 43, 20146 Hamburg, Germany, 2Dept. of Bioinformatics, Max-
Delbrück Center for Molecular Medicine, Robert-Roessle Str. 10, 13125 Berlin, Germany, 3Clinic for Surgery and Surgical Oncology, Robert-
Roessle Klinik, Charité Universitätsmedizin Berlin, Lindenberger Weg 80, 13125 Berlin, Germany, 4Children's Hospital Medical Center, Munich 
University of Technology, Parzivalstr. 16, 80804 München, Germany and 5Clinic for Surgery and Surgical Oncology, Max-Delbrueck Center, 
Robert-Roessle Str. 10, 13125 Berlin, Germany
Email: Heike Pospisil - pospisil@zbh.uni-hamburg.de; Alexander Herrmann - alexander.herrmann@mdc-berlin.de; 
Kristine Butherus - kristine.butherus@web.de; Stefan Pirson - stefan.pirson@lrz.tum.de; Jens G Reich - reich@mdc-berlin.de; 
Wolfgang Kemmner* - wkemmner@mdc-berlin.de
* Corresponding author    
Abstract
Background: Splicing processes might play a major role in carcinogenesis and tumour progression. The Wnt pathway
is of crucial relevance for cancer progression. Therefore we focussed on the Wnt/β-catenin signalling pathway in order
to validate the expression of sequences predicted as alternatively spliced by bioinformatic methods. Splice variants of its
key molecules were selected, which may be critical components for the understanding of colorectal tumour progression
and may have the potential to act as biological markers. For some of the Wnt pathway genes the existence of splice
variants was either proposed (e.g. β-Catenin and CTNNB1) or described only in non-colon tissues (e.g. GSK3β) or
hitherto not published (e.g. LRP5).
Results: Both splice variants – normal and alternative form – of all selected Wnt pathway components were found to
be expressed in cell lines as well as in samples derived from tumour, normal and healthy tissues. All splice positions
corresponded totally with the bioinformatical prediction as shown by sequencing. Two hitherto not described alternative
splice forms (CTNNB1 and LRP5) were detected. Although the underlying EST data used for the bioinformatic analysis
suggested a tumour-specific expression neither a qualitative nor a significant quantitative difference between the
expression in tumour and healthy tissues was detected. Axin-1 expression was reduced in later stages and in samples
from carcinomas forming distant metastases.
Conclusion: We were first to describe that splice forms of crucial genes of the Wnt-pathway are expressed in human
colorectal tissue. Newly described splicefoms were found for β-Catenin, LRP5, GSK3β, Axin-1 and CtBP1. However, the
predicted cancer specificity suggested by the origin of the underlying ESTs was neither qualitatively nor significant
quantitatively confirmed. That let us to conclude that EST sequence data can give adequate hints for the existence of
alternative splicing in tumour tissues. That no difference in the expression of these splice forms between cancerous
tissues and normal mucosa was found, may indicate that the existence of different splice forms is of less significance for
cancer formation as suggested by the available EST data. The currently available EST source is still insufficient to clearly
deduce colon cancer specificity. More EST data from colon (tumour and healthy) is required to make reliable predictions.
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Alternative splicing is an important source for complexity
and diversity of eukaryotic proteomes. A couple of data-
bases hold information of published alternatively spliced
forms (e.g. ASDB [1], Alternative Splicing Database [2]). A
new kind of database contains splice variants detected by
sequence comparison of transcripts and ESTs. These align-
ment based databases compare expressed sequence tags
(ESTs) either with genomic sequences [3], with UniGene
clusters [4-6] or with Ensembl transcripts [7]. An impor-
tant advantage of this approach is the possibility to detect
undiscovered splice forms [8]. In spite of some (partially
solved) problems with EST data (genomic contamination
or incomplete mRNA processing; see [9]), they may reflect
different environmental or developmental conditions.
Therefore, ESTs are an important source for the analysis of
alternative splicing which is often interpreted as a regula-
tory mechanism for certain stages in the life span of organ-
isms. In addititon, alternative splicing has been found to
be associated with various diseases including cancer [10].
The motivation for the study presented here was (1) to
validate the expression of sequences predicted as alterna-
tively spliced by bioinformatic methods, (2) to analyse
the expression of alternatively spliced genes which are rel-
evant for pathways involved in cancer formation in colon,
and (3) to try to identify splice forms which show a dereg-
ulated expression in human carcinomas.
For our experimental studies we focussed on the Wnt/β-
catenin signalling pathway, which has a central role for
colorectal tumourigenesis. Deregulated activation of this
pathway is also observed in hepatocellular carcinomas,
melanomas and uterine and ovarian carcinomas. For
instance, in about 80% of all colorectal carcinomas, the
tumour suppressor gene APC of the Wnt pathway carries
a mutation [11]. In general, the Wnt/β-catenin pathway
plays an important role for cell proliferation, differentia-
tion, and cell motility. Wnt proteins act by activating
either the "classical" Wnt pathway or one of two non-
canonical signalling cascades. Constitutive activation of
the Wnt signalling pathway due to mutations in the regu-
lator genes of the pathway (β-catenin, APC and axin)
leads to an increase in the cytoplasmic level of β-catenin
and subsequent transcription of Wnt target genes such as
c-Myc, cyclin D1 and WISP-1. An overview of Wnt path-
way components which have been found to be mutated in
human tumours is presented by Thorstensen and Lothe
[12]. According to these authors mutations in GSK-3β,
another relevant regulator molecule, have never been
reported in human cancers. This might be due to the cen-
tral role of GSK-3β in pathways other than the Wnt path-
way and due to the fact that mutations in this gene may be
incompatible with cell viability.
By bioinformatic analysis a list of putative splice variants
of relevant molecules of the Wnt pathway genes was gen-
erated. RT-PCR was then used to examine gene expression
of the putative sequences in several colorectal tumour cell
lines, but also in patient samples derived from colon can-
cer and matching normal tissue.
Results and discussions
Splicing processes might play a major role in carcinogen-
esis. For example CD44, Wilms tumour gene WT1,
BRCA1/2 and kallikrein family genes are well known and
encode cancer type related splice variants [13]. Due to the
crucial relevance of the Wnt pathway for cancer progres-
sion, splice variants of the relevant molecules may be crit-
ical components for the understanding of colorectal
tumour progression and may have the potential to act as
biological markers. For the Wnt signalling pathway, 22
genes out of 25 are predicted to have alternatively spliced
forms by EASED. Five genes involved in the Wnt signal
transduction pathway were selected with respect to their
role in the pathway. RT-PCR was used to examine gene
expression of splice forms of β-catenin (CTNNB1), axin-1,
glycogen synthase kinase (GSK-3β), C-terminal binding
protein 1 (CtBP1) und low density lipoprotein receptor
related protein 5 (LRP5) in several colorectal tumour cell
lines, but also in patient samples derived from colon can-
cer and matching normal tissue. All those genes (cf. Table
3) are important key players and differ in their function
and in their intracellular localization (Fig. 1). β-catenin
(CTNNB1) is carrying two different splice sites. Thus, we
analysed 6 EASED splice sites (Table 3). Sequence infor-
mation is given in Fig. 2A–2F. We took great care in deter-
mining optimal RT-PCR conditions in order not to miss
any less expressed splice forms. This is demonstrated for
GSK-3β (Figure 3). Annealing temperature (3A), as well as
cycling time (3B) and annealing/extension time (3C)
were optimized in order to detect both splice forms. With
the exception of CTNNB1, all splice sites are situated
within the coding DNA and lead to changes in amino acid
sequences. We used one primer set for the detection of up
to three transcripts simultaneously (Figure 4). On the one
hand, the presence of the different splice forms can easily
compared using this procedure. On the other hand the
size of the amplicon might impact the efficiency of the
reaction and the expression of longer splice forms might
be underestimated. As already known, the quantitative
value of "hand-made" RT-PCR is limited and small
expression differences will be neglected. Therefore, we
used also quantitative RT-PCR (TaqMan) for one of the
genes (Axin-1).
The PCR results for the 6 selected splice variants give
strong evidence that the algorithm used to predict poten-
tial alternative splice forms is very reliable. The selected
Wnt pathway was used as a model to test the splice variantPage 2 of 14
(page number not for citation purposes)
BMC Genomics 2006, 7:148 http://www.biomedcentral.com/1471-2164/7/148prediction algorithm. In summary, we found that always
either (1) both putative splice forms or (2) only the nor-
mal (longer) isoform are expressed in tumour and in nor-
mal mucosa. Although the underlying EST data used for
the bioinformatic analysis suggested an exclusive expres-
sion in tumours neither a qualitative nor a significant
quantitative difference between the expression in tumour
and healthy tissues was detected. However, this result is in
good agreement with Gupta et al. [14] who described that
predicted tumour-specific expression of isoforms derived
from ESTs usually tends not to reflect the experimentally
validated expression pattern.
β-catenin
Accumulation of β-catenin, a key molecule of the Wnt
pathway, in the nucleus and interaction with TCF/LEF
transcription factors leads to transcription activation of a
number of target genes such as c-Myc, cyclin D1, fra1, c-
Jun, matrilysin, CD44, urokinase-type plasminogen acti-
vator receptor and others [15]. These molecules are clearly
relevant for tumour formation, because of their roles in
proliferation, apoptosis and cell-cycle regulation. High
concentration of cytoplasmic β-catenin is critical for
growth of colorectal tumour cells [16]. Furthermore, the
results of Hlubek et al. [17] suggest that nuclear β-catenin
activates the coordinated expression of the interacting
proinvasive proteins laminin gamma 2 chain and MT1-
MMP, thereby leading to a promigratory activity at the
invasive front of colorectal cancers. Besides its role for
tumour formation β-catenin is relevant for cell-cell adhe-
sion in conjunction with E-cadherin [18]. The existence of
an additional alternative form of CTNNB1 was proposed
by Nollet et al. [19]. We found this second and hitherto
not described alternatively spliced isoform (Fig. 2B and
Fig. 4). The sequence of this splice variant is registered
under GenBank accession number AB062292. This iso-
form contains the complete intron 15 sequence as well as
the complete exon 16. The splice site is not located within
the coding region, but may affect regulatory functions of
the RNA-sequence.
CtBP1
CtBP1 might selectively repress epithelial cell adhesion
and transcription of several pro-apoptotic genes. CtBP
interacts with TCF-4, histone deacetylases and is able to
decrease the expression of the endogenous Wnt targets
[20]. Grooteclaes et al. report that CtBP-knockout cells
were hypersensitive to apoptosis [21]. The expression of
both CtBP1 splice variants was shown in colorectal
tumour as well as in normal mucosa. However, the expres-
sion of the normal 63 bp isoform was lower. The alterna-
tive isoform contains an insert of 196 bp-length within
exon 2. Due to a change of the start of the coding sequence
the predicted protein is smaller than that of the normal
isoform.
GSK-3β
The serine/threonine kinase GSK-3β binds to and phos-
phorylates several proteins in the Wnt pathway. Phospho-
rylation of β-catenin by GSK-3β leads to ubiquitination of
The Wnt-pathwayFigure 1
The Wnt-pathway. Picture taken from KEGG database http://www.genome.jp/kegg/. The selected genes involved in the anal-
ysis presented here are marked by red rectangles.Page 3 of 14
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tions of the GSK-3β gene were found in three colorectal
cancer cells [22], but further studies of cells and cancer tis-
sues are needed to test this hypothesis. The expression of
both putative GSK-3β isoforms was detected in colorectal
carcinomas and normal mucosa (Fig. 2D and Fig. 5).
These isoforms have been annotated in Ensembl
(ENST00000264235, ENST00000316626). The pro-
teinkinase-domain (56–353 amino acids [aa]) of the
alternative isoform is shorter than that of the normal iso-
form (13 aa between 304–316 aa) as shown before. This
GSK-3β splice variant was already described by Mukai et
al. [23], who localised it in human brain. Our results in
colon cancer show that this splice form is not exclusively
expressed in brain. Moreover, the hypothesis of
Thorstensen and Lothe [12] that GSK-3α may substitute
for loss of GSK-3β in tumour tissue is in agreement with
our findings.
LRP5
LDL receptor related proteins are cell surface molecules
recently identified as Wnt co-receptors. It showed no
effects on the canonical Wnt signalling by itself, but acted
synergistically to Wnt. LRP5 binds axin and recruits axin
to the membranes. Supposedly, the translocation of axin
leads to stabilisation of β-catenin and target gene tran-
scription [24]. LRP5 binds 30 or more ligands with high
affinity and delivers them to lysosomal compartments,
where they are degraded. Known ligands include lipopro-
teins, proteinases, proteinase-inhibitor complexes,
matrix-proteins, bacterial toxins and viruses, and various
intracellular proteins [25]. The presence of LRP5 corre-
lates significantly with tumour metastasis in final stage
osteosarcoma [26]. Fujino et al. showed that LRP5 is also
required in the normal cholesterol and glucose metabo-
lism [27]. Both LRP5 isoforms were found to be expressed
in colon cancer cell lines and in patient tissues (Fig. 2F,
Fig. 7). However, the expression of the alternative isoform
in the tissue samples was low. Here, we describe a new,
hitherto not published LRP5 isoform. Okubo et al. [28]
has examined the human LRP5 gene in patients with Type
III hyperlipoproteinemia by restriction enzyme fragment
polymorphism (RFLP) and described seven other
sequence polymorphisms, which means that a considera-
ble heterogeneity exists in LRP5-splicing variants. On the
protein level, the LRP5 exon skip would lead to the loss of
part of the EGF-like -Domain (PF00008). The EGF precur-
sor homology repeats in receptors are important for the
dissociation of ligands from receptors in endocytic vesi-
cles. The transmembrane domain is necessary for anchor-
ing to membranes and the cytoplasmic domain is
required for their targeting to coated pits and subsequent
internalisation [29]. The functional relevance of this loss
has to be elucidated in future studies.
Axin-1
Axin's role as a scaffold protein in the Wnt signalling is
very important for β-catenin degradation by the proteas-
ome. So, axin acts as a negative regulator and as tumour
suppressor [30]. Axin mutations were found in human
hepatocarcinomas with intact genes for β-catenin and
Alternative splice forms of selected Wnt-componentsFigure 2
Alternative splice forms of selected Wnt-compo-
nents. At top genomic DNA is depicted with all exons. In 
the middle the cDNA-structure of the normal form is given, 
the coding region is indicated in yellow, at the bottom the 
alternative isoform is shown; skips are indicated in red, 
inserts in blue. On the right side the length in bp is given of 
the pertinent sequence. For all cases, only the single splice 
event is shown. Potential other splice sites are neglected. A: 
CTNNB1(a), B: CTNNB1(b), C: CtBP1, D: GSK-3β, E: Axin-
1, F: LRP5Page 4 of 14
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PCR and quantitative real-time PCR. Exon 8 of the alter-
native isoform shows a 108 bp skip (Fig. 2E). The splice
position was examined by RT-PCR with two different
primer pairs (Fig. 6). The forward primer A (Table 1) was
positioned within the skipped sequence. Therefore only
the normal form is amplified by RT-PCR using this primer
(Fig. 6, left part). Our results show that in RT-PCR with
Axin-primer B (Fig. 6, right part) only the shorter alterna-
tive product was detected using different PCR conditions.
We suppose that the PCR reaction in this case prefers the
amplification of the short alternative product and used
RT-PCR to examine this result. Using quantitative real-
time PCR, we expected that primer T1 amplifies the nor-
mal form and primer T2 the alternative form (Fig. 8 line 1
and line 4). The results of the real-time PCR and the clin-
ical data of patients are shown in table 4, 5. Both axin-1
splice isoforms were found in the tumour tissue as well as
in healthy tissue. No differences in expression of either
normal or alternative isoforms between tumour and
mucosa were found (Fig. 9). However, in nearly all patient
samples of normal mucosa and tumour, the alternative
axin isoform was less expressed than the normal splice
variant (Fig. 9). Axin expression was reduced in later
stages (Fig 10). Similarly, axin expression is slightly
reduced in samples from carcinomas with distant metas-
tases (Fig. 11).
Determination of optimal RT-PCR conditions for detection of both GSK-3β splice formsFigu e 3
Determination of optimal RT-PCR conditions for detection of both GSK-3β splice forms. On the left (A) GSK 3β expression is 
shown in dependence of various annealing temperatures. On the right (B) side GSK 3β expression is shown in dependence of 
the number of cycles. In figure C both annealing and extension times are varied. Abbreviations: H2O, negative control; normal, 
normal GSK 3β isoform; alt, alternative splicing product.Page 5 of 14
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aa within the DIX-domain. The DIX domain is a signalling
module that is conserved in axin/conductin. In addition
to this well-documented function in mediating protein-
protein interactions, the DIX domain has been shown to
target Dvl to actin stress fibres and vesicular membranes,
and is indispensable for JNK activation by axin [32]. Axin
is incapable of dimerization if carrying mutations within
the DIX-Domain. This leads to the loss of axin's function
as a major scaffold protein for degradation of cytoplasmic
β-catenin [34]. The expression of axin was reduced in later
Axin-1 expressionFigure 6
Axin-1 expression. Axin-1 expression in LS 174T cell line and tissue cDNA from colorectal mucosa and cancer. In the left 
part of figure PCR product with primer A and in the right part PCR product with primer B. Abbreviations: H2O, negative con-
trol; normal, normal Axin-1 isoform; alt, alternative splicing product.
Expression of CTNNB1 and beta-ActinFigure 4
Expression of CTNNB1 and beta-Actin. Expression of 
CTNNB1 and beta-Actin in LS174T, SW-480 cell lines and 
tissue cDNA from colorectal mucosa and cancer. Abbrevia-
tions: H2O, negative control; normal, normal CTNNB1 iso-
form; alt.1 and alt.2, alternative splicing products.
GSK 3β expressionFigure 5
GSK 3β expression. GSK 3β expression in LS 174T cell 
line and tissue cDNA from colorectal mucosa and cancer. 
Abbreviations: H2O, negative control; normal, normal GSK 
3β isoform; alt, alternative splicing product.Page 6 of 14
(page number not for citation purposes)
BMC Genomics 2006, 7:148 http://www.biomedcentral.com/1471-2164/7/148stages (Fig. 10). Similarly, the expression of axin is slightly
reduced in samples from carcinomas with distant metas-
tases (Fig. 11). Expression of axin can be correlated
inversely with depth of invasion, lymph node metastasis
and lymphatic invasion in esophageal squamous cell car-
cinoma as shown by Nakajima [33].
Conclusion
In summary our results demonstrate the potential of bio-
informatic prediction for the search of new splice sites (as
shown for CTNNB1 and LRP5) and show the precision
and reliability of EST based prediction of the existence of
splice sites. Otherwise, the predicted cancer specificity
suggested by the origin of the underlying ESTs was neither
qualitatively nor significant quantitatively confirmed.
That let us conclude that EST data can give adequate hints
for the existence of alternative splicing in tumour tissues,
which is significant information. That no difference in the
expression of these splice forms between cancerous tissues
and normal mucosa was found, may indicate that the
existence of different splice forms is of less significance for
cancer formation as previously suggested. One source of
Table 1: Primer information (sequence, melting temperature and PCR product length) F:Forward primer, R: Reverse primer
GenBank Nr. Sequence Tm [°C] PCR products: normal/
alternative isoform [bp]
CTNNB1(a, b) NM_001904 F:GACCTCATGGATGGGCTG
R:AGGCTAGGGTTTGCTAAATTCC
60.0
60.0
329/168
CtBP1 NM_001328 F:GATGGGCAGCTCGCACTT
R: TTCATGATCGGAGGTCGGAC
59.0
59.0
63/257
GSK-3β NM_002093 F:AATGAACCCAAACTACACAGAATTTAAA
R:CAATTGCCTCCGGTGGAGT
59.0
59.0
135/96
Axin-1 NM_003502 F-A:GCGCCGGTGCTGCA
R-A: ACCCCACAGTCAAACTCGTC
F-B:GGAGGAGGAAGAAAAGAGAGCC
R-B:TGCCGATGATCTTCTCCTCAA
60.0
62.0
68.0
62.0
A:264, only normal isoform
B:428/286
Axin-1, real-time PCR NM_003502 F-T1:AGCCGTGTCGGACATGGA
R-T1:AAGTAGTACGCCACAACGATGCT
F-T2:GCACCCTCCAAGCAGAGAGA
R-T2:CGCAGAAGTAGTACGCCACAAC
59.6
58.9
59.1
58.6
T1:104
T2:94
LRP 5 NM_002335 V-A: CCCTCTACTCACCCATGGACA
R-A: AGGCACAGGTGGGAGCAG
V-B: CAGCACCCGGAAGATCATTGT
R-B: TCGTTGATCTCGGTGTTGACC
58
58
61
60
A:103, only normal isoform
B:702/571
LRP 5 expressionFigure 7
LRP 5 expression. LRP 5 expression in LS 174T, SW 480 cell lines and tissue cDNA from colorectal mucosa and cancer. 
Abbreviations: H2O, negative control; normal, normal LRP5 isoform; alt, alternative splicing product.Page 7 of 14
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and quality control in annotation of the submitted ESTs
in the past. Additionally, the differing experimental
results from database analysis can be caused to still
incomplete EST data and a bias of EST sequences towards
some tissue types and pathological states. More EST data
Table 3: Selected alternatively spliced Wnt pathway genes. NAE: the number of ESTs that predict the alternative splice form; NCE 
stands for the number of ESTs confirming the normal form. The values NAEcolcan and NCEcolcan give the respective number of ESTs 
deriving from colon cancer. The selection criteria for the several splice sites are given in the 8th column (AE: alternatively spliced ESTs, 
CE: constitutive normally spliced ESTs).
Gene Identifier 
(RefSeq/EASED)
AS-event NAE/NAEcolcan NCE/NCEcolcan Selection criteria
CTNNB1 (a) Beta-catenin NM_001904/
ENST00000301 
829 splice site 4
truncated exon 
16 (160 bp 
skipped)
34 7 47 2 (i) higher number of NAEcolcan
CTNNB1 (b) Beta-catenin NM_001904/
ENST00000301 
829 splice site 5
retained intron 
(303 bp 
inserted)
6 0 18 1 (i) 100% cancer AE (81% cancer 
CE)
(ii) unpublished splice variant
CtBP1 C-terminal binding 
protein 1
NM_001328/
ENST00000336 
543 splice site 2
retained intron 
(194 bp 
inserted)
32 2 23 0 (i) higher number of NAEcolcan
(ii) no CE from gastroint. tissues
GSK-3β Glycogen synthase 
kinase-3 beta
NM_002093/
ENST00000264 
235 splice site 1
alternative exon 
9 (39 bp 
skipped)
26 2 1 0 (i) higher number of NAEcolcan
(ii) 100% AE from cancer (no 
annotation for CE)
Axin-1 NM_003502/
ENST00000262 
320 splice site 1
alternative exon 
8 (108 bp 
skipped)
18 0 5 0 (i) 10 AE from cancer (1 CE from 
cancer)
(ii) 2 AE from stomach (0 CE 
from gastroint. tissues)
LRP5 Low-density lipoprotein 
receptor-related protein 5 
precursor
NM_002335/
ENST00000294 
304 splice site 2
alternative exon 
5 (132 bp 
skipped)
4 0 4 0 (i) 100% cancer AE (67% cancer 
CE)
(ii) unpublished splice variant
Table 2: PCR conditions, thermal cycling programs
CTNNB1 Ctbp1 (1) Ctbp1 (2) LRP 5
°C min °C min °C min °C min
activation 94 3 94 3 94 3 94 3
Steps:
strand 
separation
90 1,5 90 1,5 92 2 92 1,5
annealing 66 1 58 1 59 1 64 1
elongation 72 1 72 1,5 72 1,5 72 1,5
number of 
cycles
33 30 30 30
finale 
elongation
72 10 72 10 72 10 72 10
GSK 3β Axin-1 (A) Axin-1 (B)
°C min °C min °C min
activation 94 3 94 3 94 3
Steps:
strand 
separation
90 1,5 92 1,5 90 2
annealing 63 1 63 1 65 1
elongation 72 1 72 1,5 72 1,5
number of 
cycles
30 30 30
finale 
elongation
72 10 72 10 72 10Page 8 of 14
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required to have a statistical power to make precise specif-
icity predictions. Future work is necessary to reveal
whether there is strict correlation between a loss of e.g.
axin expression and the tumour progression or even the
formation of distant metastasis.
Methods
Prediction of splice variants with bioinformatic methods
The Extended Alternatively Spliced EST Database (EASED)
[7] project is establishing a comprehensive database of
alternatively spliced human mRNAs. Moreover, EASED
includes useful biological information and provides the
possibility to search for biologically relevant data and for
candidate genes for the origin of diseases.
All transcript sequences were extracted from the Ensembl
[35] web site and the repetitive elements have been
marked with RepeatMasker [38]. The EST sequences were
taken from dbEST [36] and were formatted for BLAST. All
transcripts were aligned with the ESTs using WU-Blast
[37] with an eValue of 0.001. The resulting high scoring
pairs (HSPs) were analysed with an in-house written Perl-
script. If one EST reveals more than one HSP with one
transcript the following filtering criteria were used: (i) the
gap between two HSPs has to be longer than 10 bp, (ii)
both HSPs have to stretch over a sequence length of more
than 30 bp, (iii) the overall identity for each HSP have to
be at least 90%. The alternative splice event was named
'skip' if the gap between two HSPs was obtain within the
transcript sequence. Otherwise it was termed as an 'insert'.
All ESTs showing these HSPs with the mentioned filtering
criteria were named as 'alternatively spliced ESTs'. The cor-
responding 'normally spliced ESTs' show one complete HSP
without any gap over the entire EST sequence length. If
possible, the HSPs from different ESTs that aligned to one
transcript were clustered as follows: all HSP with start and
end positions referring to the same transcript position (as
an uncertainty a difference of not more than 5 bp is
allowed) were merged to one single splice event. The
Table 4: Clinical data of patients. Downregulation (compared to th pool cDNA der LS 174T calibrator cell line) is marked in blue, 
whereas upregulation is shown in red (relative amounts). Tumour classification correspond to AJCC Cancer Staging Forms 6th Ed. 
(2003) http://cc.ucsf.edu/ajcc/Colon_Rectum.pdf
Patient Diagnosis
: Adeno-
carcinom
a of
death TNM classification location 
of distant 
metastasi
s
grading
G
lymphati
c vessel-
invasion
L
venous 
vessel-
invasion
V
type of 
resection
R
T N M
1943 Rectosigm
oid
no 2 0 0 2 0 0 0
1626 Colon 
ascendens
no 3b 0 0 2 0 1 0
2184 Caecum no 3c 0 0 2 0 1 0
214 Colon 
ascendens
no 3b 0 0 2 0 0 0
2456 Caecum no 3 0 0 2 0 0 0
2887 Colon 
sigmoideu
m
no 4a 0 0 2 0 0 0
2914 Rectum no 4b 2 0 2 0 1 0
398 Rectum no 3 3 1 liver 3 1 1 0
2104 Caecum yes 2 0 0 2 1 0 0
2571 Colon 
ascendens
yes 3d 2 1 liver, 
peritoneu
m
2 1 0 2
1112 Rectum yes 3b 3 1 liver, lungs 2 1 0 0
2760 Colon 
sigmoideu
m
yes 4 2 1 liver, lungs, 
peritoneu
m
2 0 0 0
2886 Caecum yes 3c 2 1 liver, 
kidney
3 1 1 0
3032 Colon 
transversu
m
yes 4 1 1 peritoneu
m
3 1 0 0Page 9 of 14
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HSP start positions and the mean of all HSP end posi-
tions.
The prediction of splice variants of investigated genes is
based on Ensembl release 19 (February 2004) with 31609
human transcripts and dbEST release from December
2003 with 5,427,257 human ESTs. All processed and
annotated alternative splice forms are stored in a MySQL
database. It allows analysing each splice site separately
instead of analysing complete transcripts. Each EST was
categorised concerning its EST library annotation. At the
moment of writing, EASED comprises four disease classes
(cancer, normal, healthy, unknown), four development
Expression of normal and alternative axin splice formsFigure 9
Expression of normal and alternative axin splice 
forms. Box-plots of constitutive normal (con) and alterna-
tive (alt) forms in carcinoma (T) and mucosa (M) (cases N = 
14).
Table 5: Axin-1 quantitative real-time PCR results. The relative amounts of the quantitative RT-PCR of axin-1 for the patients listed in 
Table 4. Downregulation and upregulation (marked with bold font) was campared to the pooled cDNA of the LS 174T calibrator cell 
line.
Patient Axin RT-PCR: relative amount
normal mucosa tumour
normal alt. normal alt.
1943 0.62 0.56 1.65 1.59
1626 1.09 0.52 0.62 1.14
2184 0.56 0.31 1.08 1.72
214 0.91 0.72 0.27 0.34
2456 1.10 0.54 1.37 0.89
2887 0.59 0.51 0.43 0.34
2914 0.39 0.26 0.40 0.26
398 1.22 0.34 1.13 0.34
2104 1.06 0.52 2.21 0.84
2571 0.54 0.35 0.40 0.28
1112 0.85 0.65 0.19 0.14
2760 0.29 0.17 2.23 1.26
2886 0.63 0.34 0.76 0.38
3032 0.11 0.17 0.32 0.34
Axin-1, primer location for real-time amplicons and electro-phoresis after real-time PCR The upper art shows th  rim r location for real-time amplicons. T1: 104 bp amplic n (n rma  isoform), T2: 94 bp ampl con (alte native i oform)Figure 8
Axin-1, primer location for real-time amplicons and 
electrophoresis after real-time PCR The upper part 
shows the primer location for real-time amplicons. 
T1: 104 bp amplicon (normal isoform), T2: 94 bp 
amplicon (alternative isoform). The lower part gives the 
electrophoresis result after real-time PCR. Line 1: LS 174S 
T1 primer product, line 2: negative control (H2O) for T1, line 
3: marker, line 4: LS 174T, T2 primer product, line 5: nega-
tive control (H2O) for T2Page 10 of 14
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tissue classes. For the web version of EASED the 193 tissue
classes were merged to 23 master classes.
In the following, we will indicate the transcript referring
to the Ensembl database as the 'normal form'. In contrast,
the EST based predicted isoform is named 'alternative
form'.
Selection of genes to be analysed
In the first selection step we searched for genes playing a
major role in the Wnt/β-catenin signalling pathway with a
higher number of alternatively spliced ESTs in colon can-
cer compared to normally spliced ESTs. To increase the
number of genes we further considered genes with a com-
parable high percentage of alternatively spliced ESTs from
other gastrointestinal tissues (as e.g. stomach) or from
cancer tissues apart from colon. To further increase the
number of candidates we examined the ratio of cancer
ESTs to the total number of annotated ESTs. Moreover, we
were interested to find out unpublished splice sequences.
The selection criteria for the several genes that were cho-
sen to be analysed are given in Table 3.
Patients and tissue samples
Fourteen consecutive cases of colorectal cancers were
examined. The patients had been treated in the Clinic for
Surgery and Surgical Oncology, Robert-Roessle-Klinik in
Berlin, Germany. Tissue samples were collected after
obtaining informed consent. Carcinoma tissues were
excised carefully from tumour specimens. Non-malignant
mucosa was also scraped off in a distance of over 50 mm
from tumour margin. Tissue was snap-frozen in liquid
nitrogen by the Tumorbank service of the Robert-Roessle-
Klinik. Carcinomas were classified and characterised
according to the World Health Organization's UICC
(Union Internationale Contre le Cancer) system: invasive-
ness (pT), lymph-node metastases (pN), primary distant
metastases (M), grading (G), lymphatic vessel-invasion
(L), venous vessel-invasion (V), type of resection (R0-, R1-
or R2) (Table 4). Seven of these patients were women and
seven were men. The age range was 51–78 years, with the
median age of 64.5 years. The range of follow-up was 3–
105 months, with a median follow-up of 46 months. The
location of the carcinomas was as follows: rectum, four
patients; colon ascendens, three patients; caecum, four
Axin-expression in correlation with stage distant metastasisFigure 11
Axin-expression in correlation with stage distant 
metastasis. Box-plots of expression values of constitutive 
normal (con) and alternative (alt) forms of Axin in cancer tis-
sue in correlation with stage distant metastasis. M = 0: no 
tumour metastasis, M = 1: distant metastasis at the time 
point of surgery (cases N = 14).
Axin-expression in correlation with tumour invasionFigure 10
Axin-expression in correlation with tumour invasion. 
Box-plots of expression values of constitutive normal (con) 
and alternative (alt) forms in correlation with stage T 
(tumour invasion). T: carcinoma, M: mucosa; t = 2: Tumour 
invades muscularis propria, t = 3: Tumour invades through 
the muscularis propria into the subserosa, or into nonperito-
nealized pericolic or perirectal tissues, t = 4 : Tumour 
directly invades other organs or structures, and/or perfo-
rates visceral peritoneum (cases N = 14).Page 11 of 14
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from a carcinoma in colon transversum. Seven patients
had metastases at the time of surgery. In the subsequent
2–4 years after surgery, six patients have died due to their
disease. Information on gender, age, stage of disease, and
histopathological factors was abstracted from the clinical
and pathological records. Furthermore, material obtained
during coloscopy from tumour free patients was exam-
ined for control purposes.
Cell lines
All cell lines were of human origin, colon adenocarci-
noma cell lines HT-29 (ATCC: HTB-38), HCT-116
(ATCC:CCL-247), LS-174T (ATCC: CL-188), SW-480
(ATCC:CCL-228), and mammary carcinoma cells MDA-
MB-435. The adenocarcinoma lines HT-29, LS-174T,
MDA-MB-435, and SW-480 were grown in Dulbecco's
modified Eagle's medium, HCT-116 was grown in Iscove's
medium, always supplemented with 10 % FBS, 2 mM
glutamine, 100 U penicillin and 0.1 mg streptomycin.
Subconfluent adherent cells were harvested by a mixture
of trypsin (0.05%) and EDTA (0.02%), rescued with their
own medium and washed with phosphate buffered saline
(PBS).
Tissue preparation and RNA extraction for RT-PCR
Cryo-sections from colorectal and normal tissue speci-
mens were transferred into RLT-Buffer containing β-mer-
captoethanol and frozen at -80°C. Only specimens
containing more than 60% epithelial cells, no Peyer's
patches and no necrotic areas were further processed. RNA
was isolated using QIAshredder and RNeasy Kits. Integrity
of isolated mRNA was checked by β-Actin One-Step RT
PCR, and RNA concentration was determined photomet-
rically. About 3 μg of RNA were used for cDNA synthesis.
In the presence of 4 μM random hexamer primer RNA was
incubated for 10 min at 70°C, then the mixture was held
on ice for another 10 min. After addition of M-MLV-
Buffer, 8 U/μL M-MLV Reverse Transcriptase, 0.8 U/μL
RNasin, 0.1 μg/μL BSA and 1.25 mM dNTP and 1 h incu-
bation at 37°C, twice the volume of absolute ethanol was
added. Following 30 min at -40°C, samples were spun
down in a centrifuge at 15,000 g at 4°C for 20 min and
washed once with 70% ethanol. Finally, cDNA was recon-
stituted in 50 μL DEPC water and frozen at -20°C.
Primer design
Primers (Table 1) used for the identification of splice var-
iants were designed so that they bind to sequences before
or after the predicted splice borders or only to the spliced
sequence itself. As a result we would expect two reaction
products which are different in length if a splice event
takes place. All primers were produced by BioTez (Berlin).
The sequences for the primer pairs were drafted using the
Primer Express 2.0 software (Applied Biosystems).
RT-PCR
RT-PCR was done mainly according to Petretti et al. [39].
The optimal concentrations, temperatures and reaction
times were determined experimentally for each individual
PCR. The target sequences were amplified in 25 μl reac-
tion volume, containing: cDNA, 2 μM dNTPs (Amersham-
Pharmacia Bioteches), 50 μM of each primer (BioTez, Ber-
lin), PCR-Buffer with 1.5 mM MgCl2 (Applied Biosys-
tems), AmpliTaq DNA polymerase (Applied Biosystems)
and DEPC-treated water (Ambion). The PCR conditions
vary for each individual gene (Table 2). Reaction products
obtained after 30 cycles were electrophoretically separated
in 2 % agarose containing ethidium-bromide. After elec-
trophoresis the gels were evaluated with the gel documen-
tation system E.A.S.Y. Win32 (Herolab). All amplicons
obtained were sequenced and compared with published
data. For extraction of the interesting RT-PCR reaction
products from the agarose gel, Qiaex II Kit (Qiagen) or
Turbo Nucleic Acid Purification Kit (Geneclean) was used.
Sequence determination was done by SEQLAB (Goettin-
gen, Germany).
PCRs were carried out for each splice (normal/alternative)
position with the cDNA of six cell lines (colonic: LS-174T,
SW-480, HCT-116, HT-29; mammary: MDA-MB-435,
MCF-7), and with RNA extracted from surgical specimens
– normal mucosa and cancer tissue of 10 patients – and
two samples of normal mucosa from healthy individuals
which underwent a coloscopy.
Quantitative real-time PCR for Axin-1
For the TaqMan assays, 5 μL cDNA extracted from patient
samples or LS174T cells, 100 nM T1 primers (normal axin
splicing form), 200 nM T2 primers (alternative axin splic-
ing isoform) and 150 nM β-Actin primers were used
(primer sequences cf Table 1).
After mixing with the appropriate volume of TaqMan Uni-
versal SYBR®GREEN PCR Master Mix, quantitative real-
time PCR was run in a MicroAmp Optical 96-Well Reac-
tion Plate using the ABI 7000 Sequence Detection System.
Thermal cycle conditions were as follows: 95°C for 10
min, initially, then 40 cycles of 95°C for 15 s and 62°C
for 1 min. Dissociation curves were generated after ampli-
fication. Data was collected and analysed with ABI PRISM
7000 Sequence Detection System thermal cycler and soft-
ware system (Applied Biosystems) according to compara-
tive CT Method in the User Bulletin.
In order to analyse expression data according to the ΔCt
method [40], Ct values were exported from the ABI Prism
7000 SDS Software into Microsoft Excel (Seattle, WA). Ct
values of a cDNA stock from the cell line LS174T were
used as calibrator. Thereby gene expression in a sample
under investigation is reported as a multiple of cell culturePage 12 of 14
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(1) wherein ΔCt stands for the difference between Ct val-
ues of gene of interest and housekeeper β-Actin.
Relative Amount =   Equation (1)
Statistical analysis
The SPSS software package version 10 was used for all sta-
tistical calculations. The Wilcoxon-signed-rank test was
applied for calculating the difference between mRNA-
expression in tumour and in mucosa of cancer patients.
Associations between mRNA-expression and established
histopathological parameters were calculated using
Mann-Whitney- and Kruskal-Wallis-tests. A significance
level of p < 0.05 was used throughout the analyses.
Authors' contributions
AH wrote the prediction software and established the
database EASED. SP participated in the selection of the
Wnt components. HP and JR provided guidance for the
computational work. KB performed the RT-PCR experi-
ments under the guidance of WK. All Authors read and
approved the final manuscript.
Acknowledgements
This work was partially supported from the Bundesministerium für Forsc-
hung und Bildung, Germany, through its contribution to the Helmholtz 
Network for Bioinformatics, and by the ATD project (funded by the Euro-
pean Commission within its FP6 Programme, LHSG-CT-2003-503329). We 
thank Ian F. Korf, Joseph A. Bedell, and Warren R. Gish for providing Mask-
erAid and WU Blast. The authors thank the reviewers for their useful com-
ments.
References
1. Dralyuk I, Brudno M, Gelfand MS, Zorn M, Dubchak I: ASDB: data-
base of alternatively spliced genes.  Nucleic Acids Res 2000,
28:296-297.
2. Thanaraj TA, Stamm S, Clark F, Riethoven JJ, Le Texier V, Muilu J:
ASD: the Alternative Splicing Database.  Nucleic Acids Res 2004,
32:D64-D69.
3. Kan Z, Rouchka EC, Gish WR, States DJ: Gene structure predic-
tion and alternative splicing analysis using genomically
aligned ESTs.  Genome Res 2001, 11:889-900.
4. Xu Q, Modrek B, Lee C: Genome-wide detection of tissue-spe-
cific alternative splicing in the human transcriptome.  Nucleic
Acids Res 2002, 30:3754-3766.
5. Krause A, Haas SA, Coward E, Vingron M: SYSTERS, GeneNest,
SpliceNest: exploring sequence space from genome to pro-
tein.  Nucleic Acids Res 2002, 30:299-300.
6. Lee C, Atanelov L, Modrek B, Xing Y: ASAP: the Alternative
Splicing Annotation Project.  Nucleic Acids Res 2003, 31:101-105.
7. Pospisil H, Herrmann A, Bortfeldt RH, Reich JG: EASED: Extended
Alternatively Spliced EST Database.  Nucleic Acids Res 2004,
32:D70-D74.
8. Roberts GC, Smith CW: Alternative splicing: combinatorial
output from the genome.  Curr Opin Chem Biol 2002, 6:375-383.
9. Modrek B, Lee C: A genomic view of alternative splicing.  Nat
Genet 2002, 30:13-19.
10. Venables JP: Aberrant and alternative splicing in cancer.  Cancer
Res 2004, 64:7647-7654.
11. Lustig B, Behrens J: The Wnt signaling pathway and its role in
tumor development.  J Cancer Res Clin Oncol 2003, 129:199-221.
12. Thorstensen L, Lothe RA: The WNT Signaling Pathway and Its
Role in Human Solid Tumors.  Atlas Genet Cytogenet Oncol Hae-
matol 2003 [http://www.infobiogen.fr/services/chromcancer/Deep/
WNTSignPathID20042.html].
13. Brinkman BM: Splice variants as cancer biomarkers.  Clin Bio-
chem 2004, 37:584-594.
14. Gupta S, Zink D, Korn B, Vingron M, Haas SA: Strengths and
weaknesses of EST-based prediction of tissue-specific alter-
native splicing.  BMC Genomics 2004, 5:72.
15. Kikuchi A: Tumor formation by genetic mutations in the com-
ponents of the Wnt signaling pathway.  Cancer Sci 2003,
94:225-229.
16. Cong F, Zhang J, Pao W, Zhou P, Varmus H: A protein known-
down strategy to study the function of beta-catenin in
tumorgenesis.  BMC Mol Bio 2003, 4:10.
17. Hlubek F, Spaderna S, Jung A, Kirchner T, Brabletz T: Beta-catenin
activates a coordinated expression of the proinvasive factors
laminin-5 gamma2 chain and MT1-MMP in colorectal carci-
nomas.  Int J Cancer 2004, 108:321-326.
18. Hulsken J, Birchmeier W, Behrens J: E-cadherin and APC com-
pete for the interaction with beta-catenin and the cytoskele-
ton.  J Cell Biol 1994, 127:2061-2069.
19. Nollet F, Berx G, Molemans F, van Roy F: Genomic organization
of the human beta-catenin gene (CTNNB1).  Genomics 1996,
32:413-424.
20. Valenta T, Lukas J, Korinek V: HMG box transcription factor
TCF-4's interaction with CtBP1 controls the expression of
the Wnt target Axin2/Conductin in human embryonic kid-
ney cells.  Nucleic Acids Res 2003, 31:2369-2380.
21. Grooteclaes M, Deveraux Q, Hildebrand J, Zhang Q, Goodman RH,
Frisch SM: C-terminal-binding protein corepresses epithelial
and proapoptotic gene expression programs.  PNAS 2003,
100:4568-4573.
22. Sparks AB, Morin PJ, Vogelstein B, Kinzler KW: Mutational analysis
of the APC/beta-catenin/Tcf pathway in colorectal cancer.
Cancer Res 1998, 58:1130-1134.
23. Mukai F, Ishiguro K, Sano Y, Fujita SC: Alternative splicing iso-
form of tau protein kinase I/glycogen synthase kinase 3beta.
J Neurochem 2002, 81:1073-1083.
24. Mao J, Wang J, Liu B, Pan W, Farr GH, Flynn C, Yuan H, Takada S,
Kimelman D, Li l, Wu D: Low-Density Lipoprotein Receptor-
Related Protein-5 Binds to Axin and Regulates the Canonical
Wnt Signaling Pathway.  Molecular Cell 2001, 7:801-809.
25. Strickland DK, Ranganathan S: Diverse role of LDL receptor-
related protein in the clearance of proteases and in signal-
ling.  J Thromb Haemost 2003, 1:1663-1670.
26. Hoang BH, Kubo T, Healey JH, Sowers R, Mazza B, Yang R, Huvos
AG, Meyers PA, Gorlick R: Expression of LDL receptor-related
protein 5 (LRP5) as a novel marker for disease progression
in high-grade osteosarcoma.  Int J Cancer 2004, 109:106-111.
27. Fujino T, Asaba H, Kang MJ, Ikeda Y, Sone H, Takada S, Kim DH, Ioka
RX, Ono M, Tomoyori H, Okubo M, Murase T, Kamataki A,
Yamamoto J, Magoori K, Takahashi S, Miyamoto Y, Oishi H, Nose M,
Okazaki M, Usui S, Imaizumi K, Yanagisawa M, Sakai J, Yamamoto TT:
Low-density lipoprotein receptor-related protein 5 (LRP5) is
essential for normal cholesterol metabolism and glucose-
induced insulin secretion.  PNAS 2003, 100:229-234.
28. Okubo M, Horinishi A, Kim DH, Yamamoto TT, Murase T: Seven
novel sequence variants in the human low density lipopro-
tein receptor related protein 5 (LRP5) gene.  Hum Mut 2002,
19:186.
29. Hussain MM: Structural, biochemical and signaling properties
of the low-density lipoprotein receptor gene family.  Front Bio-
sci 2001, 6:D417-D428.
30. Kishida S, Yamamoto H, Ikeda S, Kishida M, Sakamoto I, Koyama S,
Kikuchi A: Axin, a negative regulator of the Wnt signaling
pathway, directly interacts with adenomatous polyposis coli
and regulates the stabilization of β-catenin.  J Biol Chem 1998,
273:10823-10826.
31. Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T, Kawasoe
T, Ishiguro H, Fujita M, Tokino T, Sasaki Y, Imaoka S, Murata M, Shi-
mano T, Yamaoka Y, Nakamura Y: AXIN1 mutations in hepato-
cellular carcinomas, and growth suppression in cancer cells
by virus-mediated transfer of AXIN1.  Nat Genet 2000,
24:245-250.
32. Wong CK, Luo W, Deng Y, Zou H, Ye Z, Lin SC: The DIX domain
protein coiled-coil-DIX1 inhibits c-Jun N-terminal kinase
2
− −( ). .Δ ΔCt CtSample CalibratorPage 13 of 14
(page number not for citation purposes)
BMC Genomics 2006, 7:148 http://www.biomedcentral.com/1471-2164/7/148Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
activation by Axin and dishevelled through distinct mecha-
nisms.  J Biol Chem 2004, 279:39366-39373.
33. Nakajima M, Fukuchi M, Miyazaki T, Masuda N, Kato H, Kuwano H:
Reduced expression of Axin correlates with tumour progres-
sion of oesophageal squamous cell carcinoma.  Br J Cancer
2003, 88:1734-1739.
34. Luo W, Zou H, Jin L, Lin S, Li Q, Ye Z, Rui H, Lin SC: Axin contains
three separable domains that confer intramolecular,
homodimeric, and heterodimeric interactions involved in
distinct functions.  J Biol Chem 2005, 280:5054-5060.
35. Birney E, Andrews D, Bevan P, Caccamo M, Cameron G, Chen Y,
Clarke L, Coates G, Cox T, Cuff J, Curwen V, Cutts T, Down T,
Durbin R, Eyras E, Fernandez-Suarez XM, Gane P, Gibbins B, Gilbert
J, Hammond M, Hotz H, Iyer V, Kahari A, Jekosch K, Kasprzyk A,
Keefe D, Keenan S, Lehvaslaiho H, McVicker G, Melsopp C, Meidl P,
Mongin E, Pettett R, Potter S, Proctor G, Rae M, Searle S, Slater G,
Smedley D, Smith J, Spooner W, Stabenau A, Stalker J, Storey R,
Ureta-Vidal A, Woodwark C, Clamp M, Hubbard T: Ensembl 2004.
Nucleic Acids Res 2004, 32:D468-D470.
36. Benson DA, Karsch-Mizrachi I, Lipman DJ, Ostell J, Wheeler DL:
GenBank: update.  Nucl Acids Res 2004, 32:D23-D26.
37. Gish W: 1996 [http://blast.wustl.edu].
38. Smit AFA, Hubley R, Green P: RepeatMasker Open-3.0.  2004
[http://www.repeatmasker.org].
39. Petretti T, Kemmner W, Schulze B, Schlag PM: Altered mRNA
expression of glycosyltransferases in human colorectal carci-
nomas and liver metastases.  GUT 2000, 46:359-366.
40. Livak KJ, Schmittgen TD: Analysis of relative gene expression
data using real-time quantitative PCR and the 2(-Delta Delta
C(T)) Method.  Methods 2001, 25:402-408.Page 14 of 14
(page number not for citation purposes)
